The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Research Grant, 2020Molecular Basis of Neurodegeneration in GBA-associated Parkinson’s Disease
Study Rationale:
Studies in human genetics have implicated the malfunction of a cellular compartment called the lysosome in the pathogenesis of Parkinson’s and other brain diseases. Lysosomes are... -
Research Grant, 2021Genotyping of Lymphoblastoid Cell Lines from Familial and Sporadic Parkinson’s Disease
Study Rationale:
Our previous studies show deficits in a cell activity called centrosome cohesion in cells from people with Parkinson’s disease (PD) and a LRRK2 mutation. These deficits are reverted... -
Biosample Use Program, 2020Identification of Autoantibodies in People at Risk of Developing Parkinson’s Disease Using Microarrays
Study Rationale:
Autoantibodies are antibodies that mistakenly target and react with a person's own tissues or organs. Autoantibodies can be detected many years before symptoms develop in many... -
Therapeutic Pipeline Program, 2020Novel Candidate against Alpha-synuclein for the Treatment of Parkinson’s Disease
Study Rationale:
The goal of this program is to develop a novel drug for Parkinson’s disease with a unique mechanism of action. We have a drug candidate that shows potential as an inhibitor of alpha... -
Therapeutic Pipeline Program, 2020Photoreceptor-Directed Light Therapy in Parkinson’s Disease
Study Rationale:
Non-motor symptoms including sleep disturbances are common and enormously impact quality of life in people with Parkinson’s disease (PD). Sleep disruption affects motor function... -
Research Grant Supplement, 2020Discovery of Selective PET Imaging Agents for Tauopathies and Alpha-Synuclein
Study Rationale:
The development of alpha-synuclein and tau imaging agents will be valuable for people with Parkinson’s disease and Frontal Temporal Dementia (FTD), as deposits of these proteins...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.